What kind of nephritis does sparsentan treat?

Sparsentan (Sparsentan) is a new drug mainly used to treat specific types of nephritis. Sparsentane is primarily used to treat primary immunoglobulin A nephropathy (IgAN), a nephritis characterized by the deposition of immunoglobulin A (IgA) in the kidneys. In addition, it has been successful in trials for the treatment of focal segmental glomerulosclerosis (FSGS), suggesting that sparsantane may have therapeutic benefits in multiple types of nephritis.

For the treatment ofIgAN, sparsentane has been approved by the US FDA and is especially suitable for adult patients at risk of rapid progression. These patients usually have a urine protein to creatinine ratio (UPCR) greater than or equal to 1.5 g/g. Clinical trial data show that the use of sparsentane can significantly reduce proteinuria levels in these patients.

In an international study calledPROTECT, the therapeutic effect of sparsentine has been further verified. The results of this study show that compared with the control drug, sparsentane can reduce urinary protein more effectively, with a reduction rate of more than three times that of the control drug.

Sparsentan is a dual endothelin receptor antagonist that protects glomerular podocytes and reduces proteinuria by antagonizing the effects of endothelin and angiotensin, thereby helping to protect renal function and slow the progression of nephritis.

In summary, sparsentan is mainly used to treat primary immunoglobulinA nephropathy (IgAN) and has shown significant efficacy in clinical trials. In addition, it has been successfully tested in trials to treat other types of nephritis, showing potential for broad applications.